doctor patient situation, female doctor in consolidation with mother and child,
Syndromic testing

Tackle respiratory infections year-round

Better therapeutic precision for respiratory symptoms

We've learned to adapt to the unexpected over the past few years. But the risk of an unexpectedly severe 2023–2024 remains a real possibility. And respiratory illness still poses a significant risk to many people in our community. That's why it's more important than ever to prepare your lab with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Read on to learn how our multiplex panel tests can help you get quick, definitive answers when you need them.

The right choice for your respiratory patients is now FDA cleared

See what's new with our much-loved respiratory panel

Find out

Cycle your way to better care

A person riding a bicycle on a road

Get additional insight with cycle threshold (Ct) values

Need help navigating the complex landscape of respiratory illness? Are overlapping symptoms and confusing co-detections acting as road bocks to diagnosis?

Cycle threshold (Ct) values from QIAstat-Dx syndromic testing can give you added insights to aid in clinical interpretation.

Read on to learn how QIAstat-Dx Ct values can support you.

Don't settle for a partial pictures of co-infections

Respiratory co-infections are far from rare and can worsen symptoms (1). A recent study showed that co-detections involving two pathogens occur 12.4% of the time (2). Co-detections involving three or even four respiratory pathogens are also possible (2).

Comprehensive syndromic testing is crucial, but additional information may be necessary for clinical interpretation.

In these cases, Ct values can help. And that's where QIAstat-Dx stands out, uniquely providing easy access to Ct values and amplification curves for enhanced clinical insights.

Percentage of total respiratory detections involving two, three or four co-detected pathogens. Adapted from (2).
Percentage of total respiratory detections involving two, three or four co-detected pathogens. Adapted from (2).
I think that [Ct values] can help in the interpretation of the results, in particular in case of co-infections, in order to understand what is the virus or the bacteria that is probably more correlated with the clinical problem.
Liliana Gabrielli, MD, Microbiology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Policlinico di Sant'Orsola, Italy

Case study: Seeing beyond the respiratory symptoms with Ct values

A real clinical case resolved with results from QIAstat-Dx, provided by Xiaohui Nielsen, MD, PhD, Department of Clinical Microbiology, Zealand University Hospital, Denmark.

  • A 1-year-old child with a four-day history of fever, cough and runny nose was admitted after experiencing progressive difficulty breathing
  • QIAstat-Dx* results came back quickly as positive for: Parainfluenza virus 3 (Ct: 19); Rhinovirus/enterovirus (Ct: 32); Adenovirus (Ct: 34)
  • Outcome: With a low Ct value of 19, parainfluenza virus 3 was suggested as the etiological agent of respiratory illness, while rhinovirus/enterovirus and adenovirus were correlated with co-infection. The child recovered and was discharged after three days.
  • Ct values can add an extra layer of information to aid in clinical diagnosis and help you determine the etiology of a respiratory syndrome.
Mother holding her baby, cosy, mom, woman, close up
 

Webinar event

Female doctor examinates a girl

Webinar: Syndromic PCR testing is key to diagnostic stewardship

Join our webinar on Thursday, June 6 to learn how precise respiratory diagnostics can enhance antimicrobial stewardship and help you provide better care for your patients. Plus, participate in the live event to earn P.A.C.E. continuing education credits.

Register now

Here's what you'll gain by joining the webinar:

  1. Stay engaged in education: Participate in the live event to earn P.A.C.E. continuing education credits
  2. Understand the value of comprehensive testing: How syndromic testing can improve diagnostic accuracy
  3. Dive into antimicrobial stewardship: How targeted antibiotic strategies can improve patient outcomes
Neil Grossmann
Presenter: Neil Grossman
Director of Marketing, Infectious Diseases, North America, QIAGEN

QIAstat-Dx Respiratory Panel Plus

QIAstat-Dx, QIAstat-Dx analyzer, syndromic testing, instrument, cartridge
The right choice for your respiratory patients is now FDA cleared

Have you heard? Our much-loved respiratory panel test is now FDA cleared and has a new name – QIAstat-Dx Respiratory Panel Plus. With results for 21 viral and bacterial targets in about an hour, the QIAstat-Dx Respiratory Panel Plus can help you improve triage and infection control. And provide better care for your patients.

Get the flyer

See the targets
Lab worker handling the instrument

Get to know QIAstat-Dx

QIAstat-Dx simplifies infectious disease diagnostics so you can get faster results for your patients. All you need are a patient sample, a QIAstat-Dx assay cartridge and the intuitive QIAstat-Dx Analyzer 1.0.

  • Get answers fast: Results for several pathogens in about an hour.
  • Additional insights: See Ct values and amplification curves for additional insight on co-detections.
  • Fully customizable: Equip it with between one to four Analytical Modules to test up to four samples at once.
  • Save space: A small benchtop unit you can fit in any corner of your lab.
  • Stay connected: Real-time test updates, proactive remote service and custom epidemiology reports through QIAsphere.***

Further reading

References

  1. Liu Y, Ling L, Wong SH, et al. Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients. EClinicalMedicine. 2021;37:100955. Published 2021 Jun 10. doi:10.1016/j.eclinm.2021.100955
  2. Ali U, Zainal M, Zainol Z, et al. Performance evaluation of two multiplex qualitative RT-PCR assays for detection of respiratory infection in pediatric population. Malays J Pathol. 2023;45(2):215-227.

* This case was resolved using the QIAstat-Dx Respiratory SARS-CoV-2 Panel (Cat. No. 691214). This version of the panel is not available in the U.S. or Canada.
** Enterovirus and Rhinovirus are both detected, but not differentiated, with QIAstat-Dx Respiratory Panel Plus
*** Some features require a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your needs.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).